This book examines market access pathways for pharmaceuticals, drugs and medical devices, as well as reimbursement processes, in Germany, Austria and Switzerland. Each country study describes the key healthcare organizations and stakeholders, and analyzes outpatient and inpatient market access. The chapter on Germany highlights the implications of the Pharmaceuticals Market Reorganisation Act (AMNOG) and the Digital Health Applications (DiGA) procedures, while also examining the different market access pathways for medical devices. The chapter on Austria explores the important distinction between inpatient and outpatient systems, while the chapter on Switzerland outlines the standard procedure used by the Federal Office of Public Health and the famous Swiss Early Paid Access program. Given its scope, the book will be of interest to scholars of health economics and healthcare management, as well as healthcare professionals and business development managers.